Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21753212 | 0.98 | POLB (0.50) | POLBELANENPC1RAB9APGR | |
| SCHEMBL23288931 | 0.87 | POLB (0.50) | POLBELANENPC1RAB9APGR | |
| SCHEMBL21765257 | 0.84 | POLB (0.51) | POLBELANENPC1RAB9APGR | |
| SCHEMBL21151768 | 0.83 | MCHR1 (0.52) | POLBNPC1RAB9AARMCHR1 | |
| SCHEMBL19534278 | 0.81 | POLB (0.53) | POLBELANENPC1RAB9AUSP2 | |
| SCHEMBL21150846 | 0.78 | AR (0.57) | POLBNPC1RAB9AUSP2AR | |
| SCHEMBL21151785 | 0.78 | POLB (0.50) | POLBNPC1RAB9AARSMN1; SMN2 | |
| SCHEMBL1772431 | 0.77 | AR (0.67) | PGRAR | |
| SCHEMBL21151333 | 0.75 | OPRM1 (0.40) | POLBAROPRM1OPRL1 | |
| SCHEMBL21764931 | 0.75 | ALDH1A1 (0.53) | NPC1RAB9AUSP2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
| WO-2020039029-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | GLA, BACE1, GAA | POLB 3750/4885ELANE 3289/4885NPC1 153/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | POLB 4058/4885ELANE 261/4885NPC1 1745/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | POLB 3750/4885ELANE 3289/4885NPC1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.